In October 2011, Biogen Idec announced a collaboration with Portola Pharmaceuticals to develop and commercialize an oral, highly selective Syk inhibitor. The compound is entering a phase II trial in 2012, and we believe it could be a best-in-class oral therapy for the treatment of autoimmune and inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosus. Most recently, we acquired Stromedix, a small privately held biotech company, bringing in a promising compound for idiopathic pulmonary fibrosis, a uniformly fatal disease in which the immune system attacks and destroys the lungs. This year, we advanced the anti-TWEAK antibody for our program in lupus nephritis to phase II.